Toll Brothers Announces Final Opportunity to Own a Luxury Home at Haven Oaks in Orlando, Florida
Stunning model home is now available for sale in this exclusive community
ORLANDO, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the final opportunity to purchase a new home at its Haven Oaks community in Orlando, Florida. A limited number of homes remain available for sale in the community, including the professionally designed Frederick Elite model home.
Surrounded by mature oak trees, Haven Oaks is a private new home community featuring single-family homes in a prime location just south of downtown Orlando. Offering an array of modern one- and two-story home designs and spacious floor plans, this community brings luxury and convenience to this highly desirable area. Both move-in ready and quick move-in homes with Designer Appointed Features are available in the community, with pricing starting at $699,995.'We invite home buyers to explore the modern home designs and exceptional home sites offered at Haven Oaks before it is too late,' said Brock Fanning, Division President of Toll Brothers in Central Florida. 'With a premier location close to local shops and dining as well as world-renowned attractions, major employers, and commuter routes, Haven Oaks is an ideal place to call home in Orlando.'
Move-in ready and quick move-in homes with Designer Appointed Features are available in the community, allowing customers the opportunity to move into their new dream home on a timeline that meets their needs.
Toll Brothers residents in Haven Oaks enjoy a convenient location close to downtown Orlando and Cypress Grove Park, as well as proximity to Interstate 4 and State Road 408.
The Haven Oaks Sales Center is open daily at 52 Overleaf Lane in Orlando. For more information, call 877-431-0444 or visit TollBrothers.com/FL.
About Toll Brothers
Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations.
Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.
From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license.
Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3bb0626c-ca3e-4a3d-9930-dee18aebf30a
Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Addiction Disorders Drugs Market Analysis and Forecast to 2030: A $39.5 Billion Opportunity Led by Pfizer, Johnson & Johnson, and Indivior
Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030" report has been added to Addiction Disorders Drugs Market grew from USD 27.08 billion in 2024 to USD 28.89 billion in 2025. It is expected to continue growing at a CAGR of 6.48%, reaching USD 39.49 billion by the past decade, the addiction therapeutics landscape has undergone profound transformation, propelled by breakthroughs in neuroscience and a heightened emphasis on personalized medicine. Digital therapeutics and telehealth solutions have augmented traditional pharmacotherapy, facilitating patient adherence and extending the reach of evidence-based care. Concurrently, the approval of novel opioid antagonists and long-acting formulations has redefined maintenance strategies, enabling clinicians to tailor regimens with greater these advancements, societal attitudes toward addiction are shifting, reducing stigma and encouraging earlier intervention. Collaborations between payers and providers are driving value-based payment models, incentivizing outcomes rather than volume. Moreover, regulatory agencies are streamlining approval pathways for therapies targeting high-unmet-need indications, accelerating time to market. These transformative shifts underscore a broader trend toward integrated, patient-centric frameworks that prioritize holistic recovery over symptom the Ripple Effects of 2025 US Tariff Policies on Drug Supply ChainsIn 2025, the introduction of new United States tariffs on active pharmaceutical ingredients and drug imports has generated ripple effects across the supply chain. Manufacturers dependent on overseas raw materials have confronted increased production costs, prompting adjustments in pricing strategies and contract negotiations. These cost pressures have been most pronounced for generics and off-patent formulations, where margins are inherently mitigate the impact, several stakeholders have diversified supplier networks, exploring domestic sourcing and vertical integration initiatives. Some companies have accelerated innovation pipelines to offset higher input costs through premium product launches. Meanwhile, payers and providers are recalibrating formularies to balance budgetary constraints with clinical efficacy, favoring therapies that demonstrate robust real-world outcomes. As the market adapts to this new tariff environment, agility and supply chain resilience have emerged as critical differentiators for industry Regional Dynamics Across the Americas, EMEA, and Asia-PacificRegional analysis reveals distinct market dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, high healthcare expenditure coupled with well-established regulatory frameworks fosters rapid uptake of innovative therapies, particularly in opioid and alcohol dependence. The convergence of public and private payer systems has also facilitated broad access initiatives, driving prescription volume Europe, Middle East and Africa, heterogeneity in healthcare infrastructure and reimbursement policies yields varied adoption rates. Western European markets emphasize evidence-based formulary inclusion and tend to favor branded medications, whereas emerging economies in the Middle East and Africa show heightened demand for cost-effective generic solutions. Collaborative agreements between local authorities and multinational corporations are instrumental in expanding treatment Asia-Pacific region is characterized by escalating investment in mental health programs and an accelerating shift toward outpatient care models. Nations such as Japan and Australia are pioneering long-acting injectable therapies, while Southeast Asian countries prioritize scalable, low-cost interventions. Regulatory reforms aimed at streamlining clinical trial processes are attracting significant R&D interest, positioning the region as a key growth Leading Stakeholders Steering Innovation and Market GrowthKey players are deploying multifaceted strategies to consolidate their market positions and advance therapeutic frontiers. Leading pharmaceutical companies have fortified their pipelines through acquisitions of biotech innovators specializing in novel receptor targets and long-acting delivery platforms. Strategic alliances are enabling the co-development of combination therapies that integrate pharmacological agents with digital adherence manufacturers are leveraging scale efficiencies to penetrate value-driven markets, while niche biotech firms concentrate on underserved indications and precision medicine approaches. Contract research organizations and specialty pharmacies have also emerged as vital partners, delivering integrated services that streamline patient onboarding and support adherence monitoring. The competitive landscape continues to evolve as emerging entrants pursue orphan drug designations and expedited approval pathways, challenging incumbents to maintain agility and clinical Pathways for Industry Leaders to Navigate Future ChallengesIndustry leaders should prioritize portfolio diversification by balancing established therapies with novel modalities that address unmet needs. Investment in real-world evidence generation will strengthen payer negotiations and support value-based contracting. Cultivating partnerships with digital health providers can amplify patient engagement and adherence metrics, enhancing clinical and economic chain resilience must be reinforced through dual sourcing strategies and advanced inventory management systems to mitigate tariff and geopolitical risks. Organizations are advised to explore regional manufacturing hubs to reduce import dependencies and shorten lead times. Engaging with regulatory bodies to shape policy frameworks will facilitate faster approval pathways and market access for innovative adopting patient-centric service models that integrate pharmacotherapy with psychosocial support will differentiate offerings in a crowded marketplace. Embedding predictive analytics into care delivery can anticipate relapse risks and tailor interventions, ensuring sustained patient recovery and long-term market Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Indication Alcohol Dependence Acamprosate Disulfiram Naltrexone Opioid Dependence Buprenorphine Methadone Naltrexone Smoking Cessation Bupropion Nicotine Replacement Therapy Gum Inhaler Lozenge Patch Varenicline Stimulant Dependence Off Label Drugs Research Drugs Product Type Branded Generic Route of Administration Injectable Intramuscular Intravenous Oral Sublingual Film Tablet Transdermal Patch Dosage Form Capsule Film Injectable Solution Patch Tablet Distribution Channel Hospital Pharmacy Online Pharmacy Retail Pharmacy End User Clinics Homecare Settings Hospitals This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan The companies profiled in this Addiction Disorders Drugs market report include: Pfizer Inc. Johnson & Johnson Indivior plc Alkermes plc Camurus AB Orexo AB BioDelivery Sciences International, Inc. Titan Pharmaceuticals, Inc. Mallinckrodt plc Teva Pharmaceutical Industries Ltd. Key Attributes Report Attribute Details No. of Pages 196 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $28.89 Billion Forecasted Market Value (USD) by 2030 $39.49 Billion Compound Annual Growth Rate 6.4% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Analysts assess the potential impact of Trump's surprise 50% steel tariffs
-- U.S. President Donald Trump unexpectedly announced on Friday that steel and aluminum tariffs will double to 50%. The move, set to come into effect on June 4, was unveiled during a campaign rally in Pennsylvania. It was later confirmed on TruthSocial and comes amid broader debates around U.S. industrial policy and foreign investment. Analysts are now evaluating the implications of this surprise decision, with most agreeing that the immediate domestic effects may be less severe than the broader geopolitical risks. JPMorgan's Tatsuya Maruyama said the direct impact on major Japanese steelmakers such as Nippon Steel Corp (TYO:5401), JFE Holdings, Inc. (TYO:5411), and Kobe Steel, Ltd. (TYO:5406) is expected to be limited, given that 'the U.S. accounts for about 4% of Japan's steel exports.' Maruyama pointed out in a Monday note that Nippon Steel and JFE export only about 1% of their total shipments to the U.S., while Kobe Steel exports about 3%. Still, he warned that 'rising global protectionism' is a growing concern, noting that a wave of anti-dumping measures and safeguards in regions like South Korea, the EU, and India could further strain global trade dynamics. 'If such countermeasures gain momentum, Japanese steel products may also be targeted and the export environment may worsen,' Maruyama continued. Meanwhile, analysts at BMO Capital Markets believe the sudden tariff hike could jolt domestic markets. 'The doubling of import tariffs, if maintained, is likely to create a panic in the market and trigger a restocking cycle that in our view has the potential to push prices >$1,000/st in the near-term,' the analysts said. However, they believe the spike would be temporary given macro uncertainty and seasonal demand trends. The broker upgraded Nucor (NYSE:NUE) to Outperform but downgraded Algoma Central (TSX:ALC), which it called 'a relative tariff loser.' The aluminum market may be more exposed, according to BMO. The U.S. covers only about 20% of its own aluminum consumption domestically, making it more vulnerable to supply disruptions. 'If tariffs do double, this is expected to put material upside pressure on the Midwest premium (MWP),' BMO wrote, estimating it could reach '$0.75/lb-plus' in theory, although higher aluminum cost will likely weigh on demand and thus offset some upside pressure. That said, the brokerage sees Century Aluminum (NASDAQ:CENX) as well positioned to benefit from a rise in the Midwest premium, while Alcoa (NYSE:AA) could see a negative impact of $1–2 per share, or 4–7%, due to its reliance on Canadian production. Still, BMO expects Alcoa may redirect some of its Canadian output to the EU market. Related articles Analysts assess the potential impact of Trump's surprise 50% steel tariffs Street Calls of the Week VIDEO: How to analyze a stock like a pro with the CEO of HF Foods
Yahoo
35 minutes ago
- Yahoo
1 Value Stock on Our Buy List and 2 to Approach with Caution
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues. Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock with strong fundamentals and two best left ignored. Forward P/E Ratio: 14.5x Synonymous with "dad shoe", Skechers (NYSE:SKX) is a footwear company renowned for its comfortable, stylish, and affordable shoes for all ages. Why Is SKX Risky? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Estimated sales growth of 7.4% for the next 12 months implies demand will slow from its two-year trend Poor free cash flow margin of 4.4% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends Skechers is trading at $62.04 per share, or 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than SKX. Forward P/E Ratio: 9.9x Established in 1878, Mohawk Industries (NYSE:MHK) is a leading producer of floor-covering products for both residential and commercial applications. Why Are We Out on MHK? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth ROIC of 3.5% reflects management's challenges in identifying attractive investment opportunities, and its decreasing returns suggest its historical profit centers are aging Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned At $100.61 per share, Mohawk Industries trades at 9.9x forward P/E. Check out our free in-depth research report to learn more about why MHK doesn't pass our bar. Forward P/E Ratio: 3.7x Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Are We Bullish on SRPT? Annual revenue growth of 51.3% over the last two years was superb and indicates its market share increased during this cycle Earnings per share grew by 38.8% annually over the last five years, massively outpacing its peers Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business Sarepta Therapeutics's stock price of $37.50 implies a valuation ratio of 3.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
